Why is Parmax Pharma falling/rising?

As of 04-Sep, Parmax Pharma Ltd's stock is currently priced at 36.20, reflecting an increase of 0.89 or 2.52%. The stock has shown a performance today that outperformed its sector by 2.67%. However, it is important to note that while the stock has outperformed in the short term, it has a mixed performance over longer periods, with a decline of 3.88% over the past month and a significant year-to-date drop of 18.19%. The stock's delivery volume has drastically decreased by 95.42% compared to the 5-day average, indicating falling investor participation. Additionally, the company's negative book value and weak long-term fundamental strength, highlighted by poor growth in net sales and operating profit, contribute to a risky investment profile.
Broader market context shows that while Parmax Pharma has generated a return of 9.70% over the past year, the broader market, represented by the Sensex, has experienced a decline of 1.98%. This indicates that despite the stock's recent positive movement, it has not kept pace with the overall market performance in the long term. The stock's performance is further complicated by its negative EBITDA and weak ability to service debt, which raises concerns about its sustainability. Overall, while there are short-term gains, the underlying financial health of Parmax Pharma suggests caution for investors.